Enfusion, Inc. (NYSE:ENFN) Short Interest Up 28.7% in March

Enfusion, Inc. (NYSE:ENFN) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,300,000 shares, a growth of 28.7% from the March 15th total of 1,010,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the short-interest ratio is presently 1.1 days. Approximately 3.3% of the shares of the company are short sold.

Insider Buying and Selling

In other Enfusion news, COO Neal Pawar sold 14,560 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $165,692.80. Following the completion of the transaction, the chief operating officer now directly owns 1,217,067 shares of the company’s stock, valued at approximately $13,850,222.46. This represents a 1.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Oleg Movchan sold 11,452 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.39, for a total value of $130,438.28. Following the completion of the sale, the chief executive officer now owns 631,847 shares in the company, valued at approximately $7,196,737.33. The trade was a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,223 shares of company stock worth $754,778. Insiders own 36.44% of the company’s stock.

Hedge Funds Weigh In On Enfusion

Institutional investors have recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS purchased a new position in shares of Enfusion during the fourth quarter worth about $75,000. FNY Investment Advisers LLC bought a new position in shares of Enfusion in the 1st quarter worth $111,000. Millennium Management LLC bought a new position in shares of Enfusion in the 4th quarter worth $114,000. Harbor Capital Advisors Inc. raised its position in shares of Enfusion by 30.2% during the 1st quarter. Harbor Capital Advisors Inc. now owns 10,201 shares of the company’s stock valued at $114,000 after buying an additional 2,366 shares in the last quarter. Finally, Dark Forest Capital Management LP purchased a new position in Enfusion in the fourth quarter worth $128,000. 81.05% of the stock is currently owned by institutional investors.

Enfusion Stock Up 0.5 %

ENFN stock opened at $10.85 on Monday. The stock has a 50-day simple moving average of $11.08 and a two-hundred day simple moving average of $10.43. Enfusion has a twelve month low of $7.83 and a twelve month high of $11.80. The firm has a market capitalization of $1.40 billion, a PE ratio of 271.29, a PEG ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. On average, equities research analysts anticipate that Enfusion will post 0.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ENFN has been the subject of several recent research reports. William Blair reiterated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Piper Sandler boosted their target price on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.